Last year a Chinese scientist shocked the world by claiming that he had created the world’s first gene-edited babies. Anjana Ahuja talks to Robin Lovell-Badge, a developmental biologist and geneticist, about the controversy and about the potential for gene editing tools such as Crispr-Cas9 to revolutionise the treatment of genetic diseases.This podcast is supported by the European Federation of Pharmaceutical Industries and Associations. Read more in the FT Health series Future of Research and Development


Contributors: Joshua Noble, weekend news editor. Anjana Ahuja, science columnist, and Robin Lovell-Badge, head of the Laboratory of Stem Cell Biology and Developmental Genetics at the Francis Crick Institute. Producers: Ruth Lewis-Coste and Fiona Symon

A transcript for this podcast is currently unavailable, view our accessibility guide.

Get alerts on News in Focus when a new story is published

Copyright The Financial Times Limited 2020. All rights reserved.
Reuse this content (opens in new window)

Comments have not been enabled for this podcast.

Follow the topics in this podcast